A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

Epstein-Barr virus (EBV) positivity in diffuse large B cell lymphoma (DLBCL) provokes a critical oncogenic mechanism to activate intracellular signaling by LMP1. LMP1 specifically mimics the role of BTK-dependent B cell receptor. Therefore, a trial considering RCHOP therapy along with ibrutinib (I-R...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Sang Eun, Kim, Seok Jin, Yoon, Dok Hyun, Koh, Youngil, Mun, Yeung-Chul, Do, Young Rok, Choi, Yoon Seok, Yang, Deok Hwan, Kim, Min Kyoung, Lee, Gyeong-Won, Suh, Cheolwon, Ko, Young Hyeh, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237534/
https://www.ncbi.nlm.nih.gov/pubmed/32333154
http://dx.doi.org/10.1007/s00277-020-04005-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237534/
https://www.ncbi.nlm.nih.gov/pubmed/32333154
http://dx.doi.org/10.1007/s00277-020-04005-6

Ejemplares similares